Exicure Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Form 10-Q) | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly2.6MTarget: Sufficient capital to fund operations beyond 12 months
Quarterly Net Loss Quarterly-1.8MTarget: Reduction in cash burn through strategic partnerships and cost controls
Burixafor Clinical Development Milestones AnnuallyTarget: Initiation of IND-enabling studies and clinical trials in SCD, AML, and solid tumors
Watch Items
- Nasdaq Minimum Stockholders' Equity Requirement ComplianceTrigger: Stockholders' equity falling below $2.5 million (reported at $2.1 million as of March 31, 2026)Action: Formulate and submit a plan to Nasdaq to regain compliance, potentially through equity offerings or asset restructuring
- Going Concern Viability and Liquidity StressTrigger: Cash runway dropping below critical operational thresholdsAction: Secure dilutive or non-dilutive financing, or execute a strategic transaction/merger
- Burixafor Co-Development Progress with AdbiotechTrigger: Failure to finalize definitive agreements on budget, IP, and commercialization termsAction: Re-negotiate terms or seek alternative regional development partners
Research as of 20 Jun 2026